BLIS Technologies (BLT) H2 2025 earnings summary

Executive summary

• Achieved revenue and earnings growth for FY25, driven by disciplined execution and operational momentum.

• Addressed unexpected intellectual property issues, with negotiations ongoing to resolve patent disputes.

• Strengthened commercial foundations and delivered on key performance commitments in a challenging global environment.

Financial highlights

• FY25 revenue reached $12.6m, up 10% year-over-year, supported by finished product sales and B2B growth.

• EBITDA was $1.0m, a 26% increase from FY24 and above guidance, due to reduced regulatory expenditure.

• Net profit rose to $0.8m from $0.6m in FY24.

• Royalty revenue increased, though ingredient revenue from Europe softened.

Outlook and guidance

• Entering FY26 with cautious optimism amid mixed macroeconomic conditions.

• Focus remains on driving revenue growth in key countries, innovation in oral health, and advancing regulatory pathways.

• Continued prioritization of go-to-market strategy optimization.